I received my B.Sc./M.Sc. Degree in Biological Sciences from the University of Pavia, Pavia,
Italy (year 2000) and the Post-Graduate Specialization Degree in Laboratory Medicine-Clinical
Biochemistry from the same University (2004). I attended a competitive international (EU
framework) training program – the European School for Scientific and Regulatory Assessment
of New Medicines – at the University of Rome “Tor Vergata”, Rome, Italy (2008), where
I acquired knowledge in neuroscience, neuropharmacology, and in the area of biomarker
discovery & validation.
Over the last 13-year career, I committed myself to performing biomedical research in
Alzheimer’s disease (AD) and other neurodegenerative diseases across multidisciplinary
centers of excellence in three EU countries (Italy/Germany/France), as Post-doctoral Fellow.
I coordinated several research programs on the development/discovery of multimodal
biomarkers for AD diagnosis, with a focus on supporting the implementation of the paradigm
of precision medicine (PM) in the field of AD. In particular, I explored multidimensional
(biochemical / genetic / omics) fluid (cerebrospinal fluid [CSF] and blood [plasma/serum])
biomarkers for prediction and diagnosis of AD and for optimizing the assessment of treatment
efficacy in clinical trials, in line with the PM paradigm.
I contributed to the development of 3 successfully approved grant proposals, the most
important of which is the 5-year funded translational Research Program – “PHOENIX -
Exploring the Systems Biology and Systems Neurophysiology of Alzheimer’s Disease” (I
am Co-Principal Investigator) – at the Sorbonne University (Paris, France). The PHOENIX applies the systems biology and systems neurophysiology approaches, under the PM framework, to generate quantitative, time-dependent pathophysiological trajectories of biomarkers allowing the identification of individual and/or subgroup-specific biochemical and neurodynamic profiles of AD. I performed most of the studies in the “INSIGHT-preAD” cohort (I am Co-PI), a largescale monocentric cohort of cognitively normal individuals with subjective memory complaint, a condition associated with increased risk of AD.
I published 126 peer-reviewed papers in several prestigious and high-IF (>10) JCR journals, including The Lancet Neurology, Nature Reviews Neurology, Alzheimer’s & Dementia,
Biological Psychiatry, Ageing Research Reviews, Progress in Neurobiology, Journal
of Alzheimer’s Disease, and Neurobiology of Aging.

Reviewer Keywords